Haemonetics Company - רווח נקי למניה ב-12 החודשים האחרונים HAE
A stable geopolitical backdrop and the humanitarian status of its products minimize risks for Haemonetics Corporation (HAE). The year-over-year change in EPS (TTM) illustrates this resilience, with the latest value recorded as -34.20. This trend is supported by the development of smart plasma collection systems and IT solutions. Growth is driven by expansion in the vascular closure segment and the sale of high-margin consumables.
Haemonetics - פילוחים אנליטיים ומדדי מפתח (HAE)
The Haemonetics Corporation (HAE) model is based on high scalability driven by recurring sales of low-cost consumables following equipment installation. By analyzing the YoY EPS dynamics over the last 12 months, an investor assesses net income growth rates on a daily interval, which helps identify trend sustainability and the risk of sudden drawdowns in the absence of fundamental confirmation of business growth.
